Status:
RECRUITING
This Study Aims to Clarify the Prevalence and Characteristics of Neuropathy, Along With Associated Paraclinical Findings in Patients With Waldenström's Macroglobulinemia (WM) in a Cohort of WM Patients to Optimize the Diagnostic Process
Lead Sponsor:
Rigshospitalet, Denmark
Conditions:
Waldenstrom Macroglobulinaemia
Peripheral Neuropathies
Eligibility:
All Genders
Brief Summary
Neuropathy severely reduces patients' quality of life due to sensory loss, chronic neuropathic pain, and loss of mobility of arms and legs. Given the diverse origins of neuropathy, it is critical to i...
Detailed Description
Methods Study design: Cross-sectional observations study Outcome: Prevalence: Determining how many WM patients have neuropathy. Characterization: Identification of clinical subtypes of WM associat...
Eligibility Criteria
Inclusion
- Diagnosis of Waldenström's Macroglobulinemia with symptoms of peripheral neuropathy for further clinical investigation.
Exclusion
- Investigated with no sign of peripheral neuropathy
Key Trial Info
Start Date :
May 14 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 30 2025
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT07160270
Start Date
May 14 2025
End Date
December 30 2025
Last Update
September 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Copenhagen Neuromuscular Center, Rigshospitalet Blegdamsvej.
København Ø, Denmark, 2100